A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer (NCT06764485)

🧪 Interventions in This Study

• BMS-986365 (DRUG)
• Enzalutamide (DRUG)
• Abiraterone (DRUG)
• Docetaxel (DRUG)
• Predinsone/Prednisolone (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (281 Sites)

Showing the first 25 of 281 sites.

• Central Alabama Research — Birmingham, Alabama
• Banner MD Anderson Cancer Center — Gilbert, Arizona
• Local Institution - 0370 — Anaheim, California
• Moores Cancer Center — La Jolla, California
• Cancer and Blood Specialty Clinic — Los Alamitos, California
• Local Institution - 0364 — Los Angeles, California
• California Pacific Medical Center — San Francisco, California
• San Francisco VA Health Care System — San Francisco, California
• Local Institution - 0458 — Santa Rosa, California
• Rocky Mountain Regional VA Medical Center — Aurora, Colorado
• Rocky Mountain Cancer Centers, LLP — Denver, Colorado
• Colorado Clinical Research — Lakewood, Colorado
• Sibley Memorial Hospital — Washington D.C., District of Columbia
• Lakeland Regional Cancer Center — Lakeland, Florida
• Local Institution - 0077 — Athens, Georgia
• Northwestern Memorial Hospital — Chicago, Illinois
• The University of Kansas Cancer Center - Westwood — Westwood, Kansas
• Wichita Urology Group — Wichita, Kansas
• Chesapeake Urology — Baltimore, Maryland
• Johns Hopkins Hospital — Baltimore, Maryland
• James M Stockman Cancer Institute — Frederick, Maryland
• Local Institution - 0104 — Minneapolis, Minnesota
• Local Institution - 0049 — Las Vegas, Nevada
• Thomas Jefferson University, Kennedy Health Alliance — Sewell, New Jersey
• University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Castration-resistant Prostate Cancer

• A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — San Francisco, California
• Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Tucson, Arizona
• ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC — Sacramento, California
• FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Duarte, California
• A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer — Duarte, California
• FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer — San Francisco, California

Explore by condition: All Metastatic Castration-resistant Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.